PURPLE BIOTECH LTD.
PPBT evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for PPBT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · PPBT
Purple Biotech Ltd. is a clinical-stage biotechnology company developing a next-generation immunotherapy platform, including masked tri-specific antibodies, with a lead program CAPTN-3 and candidates IM1240 and IM1305, while also advancing CM24 and NT219 in oncology.
Key risk: History of operating losses
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Dec 31, 2025.
Purple Biotech Ltd. is a clinical-stage biotechnology company developing a next-generation immunotherapy platform, including masked tri-specific antibodies, with a lead program CAPTN-3 and candidates IM1240 and IM1305, while also advancing CM24 and NT219 in oncology.
- Purple Biotech is a clinical-stage company focused on a next-generation immunotherapy platform designed to maximize anti-cancer potency while minimizing toxicity [sec · filed 2026-03-19].
- The lead program CAPTN-3 is a platform of masked tri-specific antibodies that simultaneously target tumors while engaging both T cells and NK cells [sec · filed 2026-03-19].
- As of December 31, 2025, the company had an accumulated deficit of $171 million and expects to incur significant additional losses [sec · filed 2026-03-19].
- Cash and short-term investments are not sufficient to complete research and development of therapeutic candidates in their current phase [sec · filed 2026-03-19].
- The company plans to fund future operations through commercialization, out-licensing, and raising additional capital via debt or equity [sec · filed 2026-03-19].
What works
- The CAPTN-3 platform uses masking technology to confine immune activation to the tumor microenvironment, potentially expanding the therapeutic window versus unmasked T-cell engagers [sec · filed 2026-03-19].
- The company has a pipeline that includes both clinical-stage assets (CM24, NT219) and preclinical candidates (IM1240, IM1305), providing multiple shots on goal [sec · filed 2026-03-19].
- Purple Biotech leverages expertise in U.S. clinical and regulatory processes and a network of professional advisors to efficiently develop therapeutic candidates [sec · filed 2026-03-19].
What to weigh
- The company has a history of operating losses and expects to incur significant additional losses; it may never become profitable [sec · filed 2026-03-19].
- As of December 31, 2025, accumulated deficit was $171 million, and cash resources are insufficient to complete development of current therapeutic candidates [sec · filed 2026-03-19].
- The company depends on the success of a limited portfolio of therapeutic candidates; failure of any could impair ability to achieve profitability [sec · filed 2026-03-19].
- Each therapeutic candidate represents a novel approach, creating uncertainties in development, market acceptance, and reimbursement [sec · filed 2026-03-19].
From the filings
Quoted directly from source documents.
The company is a clinical-stage company developing a next-generation immunotherapy platform.
“We are a clinical-stage company developing a next-generation immunotherapy platform designed to maximize anti-cancer potency while minimizing toxicity.”
SEC filings · March 19, 2026
The lead program CAPTN-3 uses masked tri-specific antibodies targeting tumors and engaging T cells and NK cells.
“We are focused on advancing our lead program, CAPTN-3 - a platform of masked tri-specific antibodies that simultaneously target tumors while engaging both T cells and NK cells.”
SEC filings · March 19, 2026
The company had an accumulated deficit of $171 million as of December 31, 2025.
“As of December 31, 2025, we had an accumulated deficit of $171 million.”
SEC filings · March 19, 2026
Cash and short-term investments are not sufficient to complete R&D of therapeutic candidates.
“cash and short-term investments are not sufficient to complete the research and development of our therapeutic candidates in their current phase of development”
SEC filings · March 19, 2026
Risks & what to watch (4)›
Key risks
- History of operating losses — The company has a history of operating losses and expects to incur significant additional losses; may never be profitable [sec · filed 2026-03-19].
- Insufficient capital to complete development — Cash and short-term investments are insufficient to complete R&D of current therapeutic candidates; additional funding needed [sec · filed 2026-03-19].
- Dependence on limited portfolio — Future revenue depends on success of a limited number of therapeutic candidates; failure could impair profitability [sec · filed 2026-03-19].
- Novel therapeutic approach uncertainties — Each candidate represents a novel approach, creating uncertainties in development, market acceptance, and reimbursement [sec · filed 2026-03-19].
What to watch
- Progress of the CAPTN-3 platform, particularly IM1240 advancing toward the clinic and IM1305 in preclinical development [sec · filed 2026-03-19].
- Ability to secure additional financing through debt or equity to fund ongoing R&D and operations [sec · filed 2026-03-19].
- Outcomes of clinical trials for CM24 and NT219, and any collaboration agreements that may be established [sec · filed 2026-03-19].
- Regulatory developments and potential marketing authorization for therapeutic candidates [sec · filed 2026-03-19].
Sources: SEC filings · Generated August 11, 2026 · How we verify sources →
Run PURPLE BIOTECH LTD. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available PURPLE BIOTECH LTD. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
4.8 months
D/E 0.82
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
12
Total value held
$305K
| Holder | Shares | Value |
|---|---|---|
| susquehanna international group, llp | 53,403 | $216K |
| smartharvest portfolios, llc | 18,127 | $73K |
| bnp paribas financial markets | 1,957 | $8K |
| rhumbline advisers | 710 | $3K |
| simplex trading, llc | 597 | $2K |
| morgan stanley | 578 | $2K |
| gamma investing llc | 108 | $436 |
| group one trading llc | 20 | $81 |
| northwestern mutual wealth management co | 8 | $32 |
| jones financial companies lllp | 5 | $20 |
Showing top 10 of 12 institutional holders of PURPLE BIOTECH LTD.. Open the full 13F history after sign-in.
Short Interest
as of May 22, 2026- % of float
- 1.1%
- Days to cover
- 0.8
- Shares short
- 10,481
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
PPBT short interestFrequently asked questions
What is the AI investment thesis for PURPLE BIOTECH LTD.?
Purple Biotech Ltd. is a clinical-stage biotechnology company developing a next-generation immunotherapy platform, including masked tri-specific antibodies, with a lead program CAPTN-3 and candidates IM1240 and IM1305, while also advancing CM24 and NT219 in oncology.
Who is the CEO of PURPLE BIOTECH LTD.?
Mr. Gil Efron CPA, M.A. is the chief executive officer of PURPLE BIOTECH LTD. (PPBT).
Where is PURPLE BIOTECH LTD. headquartered?
PURPLE BIOTECH LTD. (PPBT) is headquartered in Rehovot, Israel.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.